Douglas Hanahan
道格拉斯·哈纳汉
PhD
Distinguished Scholar, EPFL; Professor Emeritus; Director Emeritus, EPFL Swiss Cancer CenterEPFL杰出学者；荣休教授；EPFL瑞士癌症中心荣休主任
👥Biography 个人简介
Douglas Hanahan is best known as co-author with Robert Weinberg of 'Hallmarks of Cancer' (Cell, 2000) and its sequel (Cell, 2011), the most cited papers in cancer biology that define the conceptual framework for the field. Beyond this theoretical contribution, Hanahan pioneered the use of transgenic mouse models to study multi-step tumorigenesis in vivo, developing the RIP1-TAG2 model of pancreatic islet carcinogenesis that revealed critical principles of the angiogenic switch, immune evasion, and invasion in solid tumor progression. His laboratory at EPFL continues to investigate therapeutic targeting of the tumor microenvironment.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Hallmarks of Cancer
Co-authored the defining conceptual framework of cancer biology, identifying the acquired capabilities (hallmarks) that distinguish cancer cells, which has guided research and drug development for over two decades.
Transgenic Cancer Models
Developed the RIP1-TAG2 transgenic mouse model of pancreatic islet tumorigenesis, enabling the first rigorous experimental dissection of multi-step tumor progression in an intact organism.
Angiogenic Switch
Used transgenic models to demonstrate that the 'angiogenic switch' is a discrete rate-limiting step in tumor progression, providing mechanistic insight into how tumors co-opt blood vessel formation.
Tumor Microenvironment
Characterized how stromal cells, immune infiltrates, and extracellular matrix components in the tumor microenvironment actively promote cancer progression and therapy resistance.
Representative Works 代表性著作
The Hallmarks of Cancer
Cell (2000)
Canonical review defining six hallmark capabilities of cancer cells; among the most cited scientific papers of all time.
Hallmarks of Cancer: The Next Generation
Cell (2011)
Updated framework adding four new hallmarks including deregulating cellular energetics and avoiding immune destruction.
Hallmarks of Cancer: New Dimensions
Cancer Discovery (2022)
Third iteration adding phenotypic plasticity, non-mutational epigenetic reprogramming, and unlocking cellular senescence as emerging hallmarks.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
Faisal Mahmood
Brigham and Women's Hospital; Harvard Medical School
Kun-Hsing Yu
Harvard Medical School; Brigham and Women's Hospital
Ziad Obermeyer
University of California, Berkeley; UC San Francisco
Andrew H. Beck
PathAI; Harvard Medical School (formerly)
关注 道格拉斯·哈纳汉 的研究动态
Follow Douglas Hanahan's research updates
留下邮箱，当我们发布与 Douglas Hanahan（École Polytechnique Fédérale de Lausanne (EPFL) / Ludwig Institute for Cancer Research）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment